Cargando…
Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study
BACKGROUND: Despite trends towards the increased age of patients living with multiple sclerosis (MS), little is known about the response of older adults with MS to disease-modifying therapies (DMTs). Thus, a post-hoc analysis was undertaken using data from a 2-year, international, non-interventional...
Autores principales: | Patti, Francesco, Penaherrera, Javier Nicolas, Zieger, Lorissa, Wicklein, Eva-Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381478/ https://www.ncbi.nlm.nih.gov/pubmed/34425763 http://dx.doi.org/10.1186/s12883-021-02347-w |
Ejemplares similares
-
Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure
por: Hellwig, Kerstin, et al.
Publicado: (2020) -
Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients
por: Stampanoni Bassi, Mario, et al.
Publicado: (2020) -
Innate and adaptive anti-viral immune responses in MS patients treated with interferon-beta
por: Petersen, Thor, et al.
Publicado: (2011) -
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b
por: Hartung, Hans-Peter, et al.
Publicado: (2015) -
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
por: Calkwood, Jonathan, et al.
Publicado: (2014)